News from 2009
Clavis Pharma Announces $380 million Partnership with Clovis Oncology
Clavis Pharma ASA and newly formed Clovis Oncology, Inc. have announced a $380 million partnership for the development and commercialisation of Clavis Pharma’s novel, patented, drug candidate CP-4126
Aegerion Pharmaceuticals Announces Additional Lomitapide Phase III Data
Aegerion Pharmaceuticals, Inc., has announced very promising additional data from its ongoing Phase III trial of lomitapide
MVM Fund III commits $5m to BioVex
MVM Life Science Partners LLP announces its investment in BioVex, a biotechnology company focused on the development and commercialisation of biological treatments for cancer and the prevention of infectious disease
Unigene Licenses Phase III Oral Calcitonin Program to Tarsa Therapeutics
Unigene and Tarsa announce that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a company newly formed by a $24 million Series A financing by MVM Life Science Partners, Quaker BioVentures and Novo A/S
Heptares Therapeutics Announces Agreement with Novartis Option Fund
Heptares has entered into an option agreement with the Novartis Option Fund, which includes upfront and potential milestone payments totaling up to $200 million plus royalties.
Vantia Therapeutics' VA111913 Enters Phase II Proof-of-Concept Trials for Dysmenorrhoea
Vantia Therapeutics announces that its novel oral small molecule drug for the treatment of dysmenorrhoea has entered Phase II proof-of-concept trials
Heptares Therapeutics Appoints Dr Barry Kenny as Chief Business Officer
Heptares Therapeutics Ltd has appointed Dr Barry Kenny as its Chief Business Officer to focus on business development and strategic alliances based on the Company’s unique StaR™ technology
Alliance Pharma plc completes acquisition of Buccastem® and Timodine® brands and vendor share placing
Alliance Pharma plc is pleased to announce the completion of the acquisition of the Buccastem® and Timodine® brands from various subsidiaries of Reckitt Benckiser Group plc for a total consideration of £7.5m.
Vantia Therapeutics’ lead candidate VA106483 demonstrates positive anti-diuretic effect in Phase IIa trial in nocturia
Vantia Therapeutics announces positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia.
Clavis Pharma ASA Announces Positive Elacytarabine Phase II Results
Clavis Pharma ASA announces positive results from a second interim analysis of the elacytarabine (CP-4055) Phase II study in patients with late stage acute myeloid leukaemia (AML).
Evotec and Roche to Develop EVT 101 for Treatment-Resistant Depression
Evotec AG and Roche have announced that they have entered into an agreement for Phase II clinical development of EVT 101 in patients with treatment-resistant depression. The potential value of this transaction exceeds US$300 million.
Heptares secures £21million Series A
Heptares Therapeutics Ltd (HTL), the drug discovery company focused on drugs targeting G-protein-coupled receptors (GPCRs), has announced that it has raised £21 million (US$30million) in a successful Series A.